急性脑损伤患者的颅内压生理、监测与个体化管理
本文为综述,总结急性脑损伤(包括创伤性脑损伤、缺血性和出血性卒中)中颅内压升高的病理生理、监测与个体化管理。传统策略依赖固定ICP阈值(如>22 mmHg)触发标准化阶梯治疗,但临床证据显示患者对ICP升高的耐受性因患者、疾病类型和生理背景差异很大。文章讨论ICP负荷、波形形态、脑自动调节和功能脑监测等新兴概念用于个体化解读ICP,并评价有创与无创ICP监测的互补价值,强调将ICP整合到评估脑灌注、氧合和代谢的多模态神经监测框架中。
要点
- 传统以固定ICP阈值(如>22 mmHg)触发标准化阶梯升级治疗,但患者对ICP升高的耐受性差异大,不宜一刀切。
- ICP既是继发性脑损伤的后果也是驱动因素,通过机械变形和脑缺血加重损伤。
- ICP负荷、波形形态、脑自动调节和功能脑监测是用于个体化解读ICP的新兴工具。
- 无创ICP监测在无法进行有创监测或存在禁忌时具有补充决策价值。
- ICP应整合到评估脑灌注、氧合和代谢的多模态神经监测框架中,未来可能借助人工智能分析复杂监测数据。
适用人群与场景
- 急性脑损伤患者,包括创伤性脑损伤、缺血性卒中和出血性卒中,处于神经重症监护管理阶段。
- 原文未提及具体的纳入/排除人群标准或急诊/院前/ICU场景限定。
诊断标准与关键阈值
- 传统管理策略使用固定ICP阈值(如>22 mmHg)触发标准化阶梯治疗,但原文指出该阈值存在争议且患者耐受性差异大。
- 原文未提及ICP负荷、波形形态、脑自动调节或功能脑监测的具体界值或评分标准。
处置流程与药物剂量
- 传统策略:以固定ICP阈值(如>22 mmHg)触发标准化阶梯升级治疗。
- 个体化策略:结合ICP负荷、波形形态、脑自动调节和功能脑监测解读ICP,而非仅依赖固定阈值。
- 无创ICP监测可用于有创监测不可用或存在禁忌时辅助决策。
- 将ICP整合到多模态神经监测框架中,评估脑灌注、氧合和代谢。
- 原文未提及具体药物、剂量、给药途径、频次或目标值。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或需立刻处理的情况。
研究设计与关键结果
- 本文为综述,未报告原始研究的设计、样本量、中心数、干预与对照或主要终点结果。
- 原文汇总的证据:固定ICP阈值(如>22 mmHg)触发阶梯治疗的传统策略存在局限,患者对ICP升高的耐受性因患者、疾病类型和生理背景差异很大。
- ICP负荷、波形形态、脑自动调节和功能脑监测等新兴概念可用于个体化解读ICP。
- 无创ICP监测在有创监测不可用或禁忌时具有补充决策价值。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未明确列出局限;作为综述,未提供原始研究数据或系统评价方法。
对床旁实践的改变
- 可能改变的做法:从统一的阈值驱动(如>22 mmHg)阶梯治疗转向基于ICP负荷、波形、自动调节和功能监测的个体化、生理学导向的颅内高压管理。
- 可能改变的做法:在有创ICP监测不可用或禁忌时,考虑使用无创ICP监测辅助决策。
- 可能改变的做法:将ICP纳入多模态神经监测框架,综合评估脑灌注、氧合和代谢。
- 适用与不适用人群:原文未明确限定;常见陷阱:仅依赖固定ICP阈值而忽略患者间耐受性差异。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute brain injury (ABI), including traumatic brain injury, ischemic and hemorrhagic stroke, is associated with high morbidity and mortality, which is driven not only by the primary brain injury, but also by the development of secondary cerebral insults. Among these, raised intracranial pressure (ICP) plays a central pathophysiological role, acting both as a consequence and a driver of ongoing brain injury through mechanical deformation and cerebral ischemia. Although invasive intracranial pressure (ICP) monitoring has a longstanding and ongoing role in neurocritical care management, the interpretation and clinical use of ICP remain controversial. Traditional management strategies rely on fixed ICP thresholds (e.g., > 22 mmHg) to trigger a standardized stepwise escalation of therapy; however, growing clinical evidence indicates that tolerance to ICP elevation varies widely across patients, disease entities, and physiological contexts. This review summarizes the physiological determinants of ICP, including intracranial compliance, cerebrospinal fluid dynamics, cerebral blood volume, and systemic factors, and describes the mechanisms underlying intracranial hypertension. We discuss limitations of using fixed ICP thresholds and highlight emerging concepts, such as ICP burden, waveform morphology, cerebral autoregulation, and functional brain monitoring, as tools to individualize ICP interpretation. The role of invasive and noninvasive ICP monitoring (nICP) modalities is reviewed, emphasizing the complementary value of nICP in guiding decision-making when invasive monitoring is unavailable or contraindicated. Particular attention is given to the integration of ICP within multimodal neuromonitoring frameworks assessing cerebral perfusion, oxygenation, and metabolism. Finally, we explore future perspectives, including the potential of artificial intelligence-based approaches to analyse complex neuromonitoring data, predict secondary insults, and move toward actionable, patientspecific therapeutic strategies. Collectively, these advances support a shift from a uniform, threshold-driven approach toward individualized, physiology-informed management of intracranial hypertension.
参考来源
- Taccone FS, Arabi Y, Baggiani M, et al. Intracranial pressure physiology, monitoring and individualized management in the acute brain injured patient. Intensive Care Med. 2026. PMID: 42525086. doi:10.1007/s00134-026-08558-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。